Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
Go back to Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 9.33 +0.33 (3.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.00 | 52 Week High | $19.41 | |||
| Open | $8.89 | 52 Week Low | $4.83 | |||
| Day High | $9.46 | P/E | N/A | |||
| Day Low | $8.78 | EPS | $-2.74 | |||
| Volume | 173,126 | |||||
